Crinetics Pharmaceuticals (CRNX) Operating Income (2017 - 2026)

Crinetics Pharmaceuticals' Operating Income history runs 10 years deep, the most recent figure standing at -$140.4 million for Q1 2026.

• On a quarterly basis, Operating Income fell 26.01% year-over-year to -$140.4 million in Q1 2026; TTM through Mar 2026 was -$545.7 million, a 44.86% decrease from a year earlier, with the FY2025 full-year figure at -$516.8 million, down 52.5% from the prior year.
• Operating Income fell to -$140.4 million in Q1 2026 per CRNX's latest filing, from -$133.7 million in the prior quarter.
• Across five years, Operating Income topped out at -$33.8 million in Q1 2022 and bottomed at -$142.6 million in Q3 2025.
• The 5-year median for Operating Income is -$73.5 million (2024), against an average of -$81.6 million.
• Across the five-year window, Operating Income tumbled 64.99% in 2022 and declined 23.12% in 2023, its largest moves.
• Year by year, Operating Income stood at -$47.6 million in 2022, then tumbled by 31.76% to -$62.7 million in 2023, then tumbled by 51.21% to -$94.7 million in 2024, then tumbled by 41.08% to -$133.7 million in 2025, then dropped by 5.02% to -$140.4 million in 2026.
• Per Business Quant, the three latest CRNX Operating Income figures stand at -$140.4 million (Q1 2026), -$133.7 million (Q4 2025), and -$142.6 million (Q3 2025).